Industries Lowest Current-Voltage 2-Wire Inductive Proximity Sensor [3 µA, +2.3V]

Frequency Control Products & Inductive Proximity Sensors Manufacturer

Mercury United Electronics, Inc.

Mirow Brand Inductive Proximity Sensors deliver a "True-Off" feature when safety is critical

RANCHO CUCAMONGA, CALIFORNIA, UNITED STATES, February 27, 2020 /EINPresswire.com/ — PRESS RELEASE:

February 26, 2020

Industries Lowest Current-Voltage 2-Wire Inductive Proximity Sensor [3 µA, +2.3V]

Mercury United Electronics, Inc. announces the release of their new True-Off™ Series (M18M2) 2-Wire Inductive Proximity Sensors. The True-Off™ Series is the industry’s lowest operating current and voltage 2-wire Inductive Proximity Sensor.

This True-Off™ Series utilizes the patented Mirow Brand Sensors technology to operate at the industry’s lowest off-state leakage current (residual current) level of 3 µA (typ.) and the lowest “on”voltage level of +2.3V, making it ideal for low current portable/battery operated applications. A short YouTube video demonstrating the performance advantages can be viewed at the following link: https://youtu.be/d7wlVLCkx8M.

The low minimum operating voltage of +2.3V also makes this sensor directly compatible with most types of computers for portable robotics, motor controls, and automation. This sensor provides excellent results with difficult-to-detect objects that use aluminum or copper metals.

Features:
• Ultra-low off-state leakage current: 5 µA max.
• Ultra-low on-state holding current: 20 µA min.
• Low minimum operating voltage: +2.3V min.

Additional information and datasheets can be found at:
https://mercuryunited.com/index.php?route=information/information&information_id=47

About MERCURY

Mercury United Electronics, Inc. has manufactured quartz crystals and clock oscillators since 1973, headquartered in Taiwan, now offering the industry’s lowest operating power inductive sensor for the consumer market where low voltages and currents are critical.

CONTACT:
Art Trejo, National Sales Manager
Art-Trejo@MercuryUnited.com
(T) 909-466-0427 ext. 33
Mercury United YouTube Channel: https://www.youtube.com/channel/UC6jM4yFQ0EZcs8AObSqVn1Q

Art Trejo
Mercury United Electronics, Inc.
+1 909-466-0427
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Inductive Proximity Sensor Leakage Current Demonstration – See how the Mirow Brand M18M2 2-Wire Inductive Proximity Sensor compares with Brand X.


Source: EIN Presswire

DOE Aims at $4.6 Billion to Convert Ill-Constructed MOX Plant into Plutonium Bomb Plant (PBP) at Savannah River Site

DOE Plans for Plutonium Bomb Plant (PBP) in Terminated Plutonium Fuel (MOX) Buiding at Savannah River Site. $8 billion was wasted on MOX and congressional investigations needed. Photo used with permission, courtesy of High Flyer

Presentation to Sierra Club (John Bachman Group) on Proposed Plutonium Bomb Plant (PBP) at Savannah River Site, by Tom Clements, director SRS Watch, January 27, 2020, Columbia, SC; photo by Paul Palmer

Production of 4000 new plutonium “pits” (cores) in a Plutonium Bomb Plant (PBP) at SRS and in new facilities at Los Alamos National Lab – for pits for unneeded new and “refurbished” nuclear weapons – poses risk of costly and dangerous nuclear arms race

As U.S. DOE Prepares for New Nuclear Arms Race, $442 Million Request in Fiscal Year 2021 for Plutonium Bomb Plant at SRS – Revealed in Feb 26 NNSA Budget Volume

Preparation for a Plutonium Bomb Plant at DOE's Savannah River Site would have an unwarranted financial cost, while stimulating a new nuclear arms race. Congress must reject this dangerous project.”

— Tom Clements, Director, Savannah River Site Watch, Columbia, South Carolina

COLUMBIA, SOUTH CAROLINA, US, February 27, 2020 /EINPresswire.com/ — A budget document released by the U.S. Department of Energy late on Wednesday, February 26 reveals that the agency has assumed a stunning projected cost of $4.6 billion to convert the poorly constructed plutonium fuel (MOX) building at the Savannah River Site – near Aiken, SC – into a Plutonium Bomb Plant (PBP). This amount of spending reveals that DOE and contractors aim to repurpose the failed MOX project into a perpetual money machine, according to the public interest group Savannah River Site Watch (https://srswatch.org/).

The budget document, the National Nuclear Security Administration’s funding request to Congress for Fiscal Year 2021, confirms that the agency is seeking $441 million for “repurposing” the MOX building into the unjustified Plutonium Bomb Plant. The massive amounts of requested or anticipated funds reveal that the MOX plant is in poor shape and internal components, such as piping and HVAC systems, will have to be ripped out and much construction reworked. (Link to most recent MOX photos posted here.)

“Plans to throw vast sums of our money at an unjustified, rushed Plutonium Bomb Plant, central to a new nuclear arms race, is a DOE formula for failure and, like the mismanaged MOX project, is guaranteed to run far over budget and fall far behind schedule,” according to Tom Clements, director of SRS Watch. “Sadly, it is no surprise that the failed MOX project, on which $8 billion was wasted, is turning into a money machine for private contractors who aim to feed off creation of a Plutonium Bomb Plant at SRS,” added Clements. The Plutonium Bomb Plant would make plutonium “pits” (or triggers, which cause the nuclear explosion) for thousands of nuclear new and refurbished nuclear weapons, all part of a new plan to engage in a dangerous and costly new nuclear arms race.

The overall DOE budget request reveals a massive increase in nuclear weapons activities. The NNSA request is up 18.4% from Fiscal Year 2020, to $19.8 billion. The Weapons Activities’ budget request is $15.6 billion, up 25.2 percent above the FY 2020 enacted amount, according to a NNSA news release of February 10, the day top-line items of the budget were released. Meanwhile, the DOE site clean-up budget absorbs the brunt of the increase in pit production, from about $7.5 billion appropriated in FY20 to a FY 21 request of $6.1 billion. “The huge decrease in clean-up funding and exploding increase in nuclear weapons reflects reversed, unjustifiable budget priorities,” according to Clements.

The NNSA budget request (on page 199) reveals the stunning sums of money it seeks to make 50 or more plutonium pits per year at SRS by 2030, a site that has had zero experience in handling pits, zero experience in casting liquid plutonium and little experience in processing plutonium since all five production reactors ceased operation in the late 1980s:

"This project was initiated in FY 2019 utilizing Other Project Costs (OPC) funding in the Plutonium Sustainment Program. Critical Decision (CD) 0, Approve Mission Need, for the “Plutonium Modular Approach” was approved on November 25, 2015 with a preliminary Total Project Cost (TPC) range of $1.3B to $3.0B with a project completion schedule range of December 2025 to December 2027. The most recent cost and schedule estimates were developed during the Plutonium Pit Production Engineering Assessment (EA) in 2018 with an estimated construction high end of the cost range at $4.59B and a CD-4 schedule range of July 2026 to January 2030. … The Mission Need Statement was revised in March 2019 for the now titled “Savannah River Plutonium Processing Facility (SRPPF)”."

"The FY 2021 Request for Savannah River Plutonium Modernization and Pit Production is $441,896,000 which includes $241,896,000 for construction design, $110,000,000 for Other Project Costs (OPC) funding in the Savannah River Plutonium Operations Program for the planned project, Savannah River Plutonium Processing Facility, and $90,000,000 for Plutonium Modernization work to support the capability to produce 50 pits per year at Savannah River."

As it rushes headlong with plans for pit production at SRS, NNSA is also planning on a massive spending increases at the Los Alamos National Laboratory in New Mexico to make 30 or more pits per year by 2026. The pit-related request for Los Alamos in Fiscal Year 2021 is a stunning $884,599,000.

NNSA is refusing to review reuse of over 15,000 pits stored at DOE’s Pantex site in Texas and has so far refused to take another serious look at pit lifetime. A 2007 study entitled “Pit Lifetime” – https://fas.org/irp/agency/dod/jason/pit.pdf – by the JASON group for NNSA, said that most pit types “have credible minimum lifetimes in excess of 100 years as regards aging of plutonium.”

SRS Watch, along with fellow members of the Alliance for Nuclear Account Ability (ANA) – Nuclear Watch New Mexico and Tri-Valley CAREs – are reviewing legal options given NNSA’s failure to prepare the mandated Programmatic Environmental Impact Statement (PEIS) to review system-wide impacts of pit production. Underscoring the need for the PEIS, the current DOE budget request reveals that a host of sites beyond SRS and Los Alamos are involved in pit activities. An analysis of NNSA’s budget request by Nuclear Watch New Mexico reveals that NNSA “has requested $1.58 billion for expanded plutonium pit production in FY 2021 alone.”

###

Notes:

See DOE FY 21 budget request for NNSA – volume 1 – posted late afternoon, Feb 26, 2020:
https://www.energy.gov/cfo/downloads/fy-2021-budget-justification
https://www.energy.gov/sites/prod/files/2020/02/f72/doe-fy2021-budget-volume-1.pdf

NNSA news release on budget request, February 10, 2020:
https://www.energy.gov/nnsa/articles/fy-2021-presidential-budget-nnsa-released

NNSA’s 293-page ‘Pu Pit Production Engineering Assessment” is available at:
https://nukewatch.org/importantdocs/resources/Pu-Pit-Engineering-Assessment-Report-Rev-2_20-April-2018.pdf

"NNSA should focus on cleanup," by Ralph Hutchison, coordinator of the Oak Ridge Environmental Peace Alliance (OREPA) – a member of the Alliance for Nuclear Accountability – in Oak Ridger newspaper, Feb. 26, 2020:
https://www.oakridger.com/news/20200226/guest-column-nnsa-should-focus-on-cleanup

Thomas Clements
Savannah River Site Watch
+1 803-834-3084
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

REDBUD LABS Expands STR Chip Offering

STR BeadPak, Redbud Labs' cartridge-ready sample prep microfluidic chip

Redbud Labs’ STR BeadPak chip

Company expands chip offering with introduction of STR™BeadPak, the only universal, ready-to-use microfluidic sample prep solution available for POC cartridges.

Since we launched STR™ last year, we’ve gotten questions about what functional chemistries it would support. Today, we have an answer: all of them.”

— CEO, Richard Spero

RESEARCH TRIANGLE PARK, NORTH CAROLINA, UNITED STATES, February 27, 2020 /EINPresswire.com/ — Redbud Labs announced today an expansion to its cartridge-ready STR™ (“sorter”) microfluidic chip family with the introduction of STR™BeadPak. STR™BeadPak combines the company’s proprietary Redbud Post® technology with off-the-shelf magnetic beads to enable system developers to instantly port their sample prep workflows onto microfluidic cartridges. This product line extension means Redbud’s STR™ chip line is now backwards-compatible with a vast catalogue of existing life science workflows, making STR™BeadPak the most versatile sample prep solution for sample-to-answer system developers. STR™BeadPak chip can be employed during biomarker discovery, through platform development, and into volume production.

STR™BeadPak is compatible with magnetic beads of virtually any size and surface functionalization, including antibody, oligomer nucleotide, or a generic binding moiety such as neutravidin. Potential workflows include immunoassays, nucleic acid purification, and sorting of extracellular vesicles, microbes, and cells. Based on the same highly adaptable design used for all of Redbud’s products, STR™BeadPak is available immediately for testing. Developers can perform their own testing using starter kits in their own facilities or let Redbud port their existing assays to STR™BeadPak for them.

“Since we launched STR™ last year, we’ve gotten questions about what functional chemistries it would support. Today, we have an answer: all of them. STR™BeadPak is the first product of its kind. It empowers system developers to continue using the magnetic beads they know and trust, with full confidence that they have a path to a cartridge-based solution down the road,” said Richard Spero, CEO.

STR™BeadPak is the only universal, ready-to-use microfluidic sample prep solution available. It builds on STR’s track-record, delivering industry leading speed. In a recent study, STR™BeadPak captured 94% of targets in 5 minutes, compared to only 9% for an on-cartridge method, and achieved 1,000x faster target capture versus a conventional on-cartridge method. STR™BeadPak is designed to accelerate development of high-performing sample-to-answer systems by solving the persistent challenge of microfluidic sample preparation.

ABOUT REDBUD

Redbud Labs, headquartered in Research Triangle Park, North Carolina, manufacturers breakthrough components for life science industry, intended to solve the industry’s ubiquitous microscale fluidic challenges. Redbud technologies, powered by Redbud Posts®, have broad application across a variety of segments including basic research, drug discovery and development, biomanufacturing, diagnostics, sequencing and applied markets. Redbud Posts are an array of flexible, magnetic micropillars printed on a silicone film that can be affixed to a substrate. Redbud Posts rotate in response to a magnetic field, inducing microfluidic agitation for rapid and efficient target capture. Industry partners seek Redbud’s proprietary microchip technology, component design expertise and deep scientific know-how to advance their own next generation products. Rebudlabs.com

Kathryn Lawrence
Redbud Labs Inc.
+91 95379 75397
email us here


Source: EIN Presswire

Swittons Debuts First Fully Customizable IoT Powered Solution to Improve Pharma to Physician Communication

Swittons Improves Pharma to Physician Communication

Smart device helps pharmaceutical reps cover more territory and gives physicians flexibility when it comes to consultations and orders

At Swittons, we have reimagined the world of pharma to physician communication by fundamentally changing the way marketers and sales organizations interact with customers and prospects.”

— Swittons CEO and Founder Anupam Nandwana.

PISCATAWAY TOWNSHIP, NEW JERSEY, UNITED STATES, February 27, 2020 /EINPresswire.com/ — Swittons, a P360 company, has launched the first fully customizable IoT powered solution for pharmaceutical commercial organizations and physicians. Swittons enhances the pharma to physician relationship by helping representatives cover more territory, and by breaking down communication barriers to office visits, professional consultations and product orders. The smart device can also be configured for biotech and medical device sales organizations.

“At Swittons, we have reimagined the world of pharma to physician communication by fundamentally changing the way marketers and sales organizations interact with customers and prospects,” stated Swittons CEO and Founder Anupam Nandwana. “Our solution not only saves organizations time and money, it gives them a new digital channel of engagement for meaningful interactions. From dashboard to devices to data, Swittons powers seamless engagement.”

Swittons is designed to be compatible with existing commercial infrastructure and integrates seamlessly with leading CRM and ERP systems. The device, which can be custom branded, comes programmed to execute up to four different predefined functions. Bringing critical data from a device to the enterprise has never been easier, because Swittons takes care of all the complex technical work.

As the cost of doing business goes up, and regulations become more restrictive, pharmaceutical sales organizations are increasing their demand for innovative products that help them remain competitive. Swittons helps in the following ways:

• Solves the “whitespace” problems by enabling communication with physicians who were previously untargeted, because of remoteness or other reasons.
• Boosts the launch of new brands by increasing brand awareness and sample facilitation, etc.
• Adds additional coverage for sales teams that have downsized.
• Helps physicians order samples faster (or product, for “buy & bill” offices).
• Creates a new channel of communication with physicians, something they are asking for.

Physicians appreciate Swittons because the device enables them to be in better control of their schedule. At the click of a button, they can request samples, schedule sales visits, book medical science liaison (MSL) consultations and access important medical information. And since the 4-inch device takes up very little desk space, it is conveniently available and integrates seamlessly with physician workstyles. The smart devices can be preprogrammed with individualized functionality as well.

For physicians that receive Swittons, the device comes out of the box ready and automatically connects through a Wi-Fi or GSM cellular connection (GSM service provided by Swittons). More information about Swittons for Physicians is available HERE.

Swittons is powered by the technology and expertise developed by P360. Delivering a 360 view through the pharma, physician and patient ecosystem, P360 designs and deploys capabilities that ensure the highest efficiencies and returns on sales operations, data management, clinical trials, patient centricity, and IoT innovation. Swittons is built on Microsoft Azure.

To learn more about Swittons for pharma, simply visit Swittons.com/pharma. To learn more about P360, go to P360.com.

About Swittons
Based in Piscataway Township, New Jersey, and powered by P360, Swittons is an end-to-end enterprise IoT solution for commercial acceleration. From dashboard to device to data, Swittons powers seamless engagement. Swittons for physicians and pharma is changing everything about how businesses communicate. To learn more, visit Swittons.com.

Brian Fitzgerald
Swittons
email us here
+1 8087540437
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Workshop Teaches Movement-Based Strategies for Emotional Regulation in Children with Autism

Occupational Therapist Alexa Moses, MS, OTR/L. presenting workshop.

Occupational Therapist Alexa Moses, MS, OTR/L. presenting workshop

Workshop audience

Large and diverse audience interested in learning important educational strategies.

Shema Kolainu – Hear Our Voices presented a workshop at Touro College free of charge through the generosity of the New York City Council Autism Initiative.

Alexa has conducted many outstanding SKHOV workshops throughout the years, sharing her insights and expertise with educators and parents alike”

— Dr. Joshua Weinstein, founder and CEO of Shema Kolainu

BROOKLYN, NY, UNITED STATES, February 27, 2020 /EINPresswire.com/ — On Wednesday, Shema Kolainu – Hear Our Voices (SKHOV) hosted "Using Movement Strategies to Improve Emotional Regulation,” a free workshop at Touro College focusing on emotional regulation in children with autism spectrum disorder (ASD). The event attracted a large, diverse audience interested in learning important educational strategies.

The interactive workshop was hosted by SKHOV occupational therapist Alexa Moses, MS, OTR/L. “Alexa has conducted many outstanding SKHOV workshops throughout the years, sharing her insights and expertise with educators and parents alike,” said Dr. Joshua Weinstein, founder and CEO of Shema Kolainu.

During the workshop, participants learned innovative techniques and exercises to help those with autism more effectively regulate their emotions while providing ways to build strength and improve motor functions. Moses shared valuable educational strategies and informative insights into understanding, recognizing, and regulating emotions in children and young adults with ASD.

“We want to train children with autism to name the emotion they experience, as well as how to associate it with a triggering event,” Moses explained. This can be done through “mitigating,” which is when a teacher or parent modifies the environment to help the child self-regulate. She also described the importance of identifying negative “self-talk” and restructuring it in a positive frame of mind, which can help with emotional regulation. She added that students with autism need to be given different strategies for problem-solving that they are able to apply in various settings and situations.

Take-home materials were distributed to help people with ASD improve interactions with family members, patients, and students.

The workshop, along with all others by SKHOV, was provided free of charge through the generosity of the New York City Council Autism Initiative.

Through a partnership with Touro College, SKHOV hopes to provide more educational workshops for guests seeking to help people with ASD.

Shema Kolainu – Hear Our Voices founded by Dr. Joshua Weinstein, offers a broad spectrum of evidencebased education and therapeutic programs to children with Autism Spectrum Disorder, (ASD) and related disabilities in a warm and nurturing environment. A nonpublic, nonprofit, multi-cultural school, we provide quality treatment, education, professional training and mentoring.

Joshua Santos
Shema Kolainu – Hear Our Voices
+1 718-686-9600
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Using Movement Strategies to Improve Emotional Regulation – Shema Kolainu – Hear Our Voices Workshop


Source: EIN Presswire

Registration is open for SMi's 4th Annual Pharmaceutical Microbiology West Coast 2020

SAN DIEGO, CA, UNITED STATES , February 27, 2020 /EINPresswire.com/ — SMi Reports: The 4th Annual Pharmaceutical Microbiology West Coast Conference will convene in San Diego on June 18th and 19th 2020 to discuss the latest innovations and challenges within the industry

Following on from the success of last year, SMi Group proudly presents the 4th Annual Pharmaceutical Microbiology West Coast Conference, taking place in San Diego, USA, on June 18th and 19th 2020.

The event will bring together microbiology experts to discuss novel approaches and best practices for tackling current industry contamination control challenges. Microbes such as bacteria, fungi, parasites and viruses that can contaminate current and novel pharmaceutical products or therapies may stem from various sources such as raw materials and human operators, are taken into consideration.

Registrations made before February 28th will receive a US$400 discount, or save US$200 thereafter from the full conference price: http://www.pharma-microbiology-usa.com/EINpr1

This concern is critical in advanced products/therapeutics facilities where often distinct areas within manufacturing are slowly merging, providing potential new sites for contamination events. The conference showcases sessions that cover alternative endotoxin testing and rapid mycoplasma testing as well as implementation of in-line biodurden monitoring to control water systems, to name a few. Due to the complexities brought about by more advanced therapeutic products, both drugs and patients are time dependent and rapid methods are ever more desired.

A significant portion of the conference will focus on contamination control strategies and facilities support/novel technologies such as a looking at a sustainable global contamination control program, cleanroom pass thru best practices and a case study executing rapid transition from clinical to commercial manufacturing and more. There will also be a regulatory session discussing objectionable organisms in non-sterile drug products and an all-women panel discussion: ‘Culturing’ Successful Women Microbiologists.

Key highlights for 2020 include:
• Discuss the guidance, regulations and case studies for objectionable organisms in non-sterile drug products from ValSource, Inc.
• Gain insight into changing paradigms – moving to in-process testing from Johnson & Johnson
• Examine alternative endotoxin test methods for products exhibiting LER from Amgen
• Explore how to effectively scale up from clinical to commercial in three moves from Bristol-Myers Squibb
• Join us for our first All-Women Panel Discussion on ‘Culturing’ Successful Women Microbiologists

There will also be a half-day interactive workshop on Wednesday June 7th on “Data Integrity in Environmental Monitoring: Causes and Solutions,” which will be led by Ziva Abraham, CEO/President, Microrite and Morgan Polen, SME, Cleanroom Contamination Control Expert, Microrite.

To register for the event or find out more, visit: htpp://www.pharma-microbiology-usa.com/EINpr1

— ENDS –

Pharmaceutical Microbiology West Coast 2020
Conference: June 18 – 19, 2020
Interactive Workshop: June 17, 2020
Hyatt Regency Mission Bay Hotel, San Diego, CA, USA
http://www.pharma-microbiology-usa.com/EINpr1
#SMiPharmaMicroWC

For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6164 or amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or ssapal@smi-online.co.uk

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Simi Sapal
SMi Group
+44 20 7827 6000
email us here


Source: EIN Presswire

Artificial Knee Joint Market 2020, Global Industry Analysis, Size, Share, Growth, Trends and Forecast – 2025

A New Market Study, titled “Artificial Knee Joint Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.

PUNE, MAHARASTRA, INDIA, February 27, 2020 /EINPresswire.com/ — Summary

A New Market Study, titled “Artificial Knee Joint Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.

This report provides in depth study of “Artificial Knee Joint Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Artificial Knee Joint Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This market report offers a comprehensive analysis of the global Artificial Knee Joint market. This report focused on Artificial Knee Joint market past and present growth globally. Global research on Global Artificial Knee Joint Industry presents a market overview, product details, classification, market concentration, and maturity study. The market value and growth rate from 2019-2025 along with industry size estimates are explained.

This report focuses on the global top players, covered
 B. Braun
Smith & Nephew
Zimmer Biomet Holding Inc.
Stryker
Exactech
Johnson & Johnson
DJO Surgical
Medtronic
Becton Dickinson
Arthrex, Inc.
ConforMIS
MicroPort Scientific Corporation
OMNI life science

Request a Free Sample Report @ https://www.wiseguyreports.com/sample-request/3816922-global-artificial-knee-joint-market-data-survey-report-2013-2025

Report Summary:
In the first section, the Global Artificial Knee Joint Market report presents industry overview, definition, and scope. The second part briefs about the Global Artificial Knee Joint industry bifurcation by Type, Application and Geographical regions. The top industry players, revenue analysis, and sales margin are explained. The production and consumption scenario is specified.

The SWOT analysis by players, the growth rate for each type, application, and the region is covered. A 5-year forecast Global Artificial Knee Joint industry perspective will lead to profitable business plans and informed moves. Towards, the end data sources, research methodology, and findings are offered.

Market Overview 
Artificial Knee Joint is one of the exponentially demanded services since they come of great use for helping the differentially abled people, people who have dysfunctional joints either due to an accident or a certain diseased condition or simply old age. The market has witnesses proliferation in the past few years because of exponential growth of demand from the end-users. There have been some driving factors that accelerate the global market, and also a few restraining factors that decelerated growth in the market.

There are several types of Artificial Knee Joint and all these variations have been introduced long ago. Apart from the existing ones manufacturers and researchers continue to further create new variations designed for meeting the specific requirements, which has led to the expansion and growth of the Artificial Knee Joint market. As per the forecast, the trend of increased consumption and demand will continue during the forecast period since there has been an increasing number of manufacturers and services providers as well, who are reaching the prospective customers through different channels.

Market Segmentation 
Artificial Knee Joint Hospitals, Artificial Knee Joint for Specialized Orthopedic Clinics, and Artificial Knee Joint for Ambulatory Surgical Centers: following are the geographical market segments on the basis of product type and their specification. Since the product has penetrated into different geographical locations, there are also a great number of sub-sections that can be witnessed on deeper analysis of the global market. The product reach is however limited in some regions, depending on the demand and supply rate. Manufacturers offer services as per the demand from the customers. The same market can also be segmented on the basis of end-users and how they are used by different user/sector for different purposes. Global market classification on the basis of end-user are as follows: Stainless Steel Artificial Knee Joint, Cobalt-chromium Artificial Knee Joint, Alloys, Titanium Artificial Knee Joint and Titanium Alloys Polyethylene Ceramics.

Regional Overview 
Europe (Germany, UK, France, Italy, Russia, and Turkey, etc.) and South America (Brazil etc.): following are the regions where product demand has been increasing and it’s where majority of the manufacturers and suppliers’ acquisitions are. Secondary markets with a significant number of service providers or manufacturers and also significant consumption rate are as follow: North America (the United States, Canada, and Mexico) and The Middle East and Africa (North Africa and GCC Countries). Given the increasing world economy, the ever-increasing world population and life-expectancy, following regions are also expanding their user base and there has also been an increasing number of small business startups with distribution in local areas and market. Some of the exponentially growing markets are as follows: Asia-Pacific (China, Japan, Korea, India), Australia and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam)

Industry News 
The usage of social media and internet marketing has increased opportunities for the sellers, and it will continue to do so. Gradually, new designs for Artificial Knee Joint are developed in many parts of the world.

Major Key Points in Table of Content

1 Global Market Overview

2 Regional Market

3 Key Manufacturers

4 Major Application

5 Market by Type

6 ConclusionFig Global Artificial Knee Joint Market Size and CAGR 2013-2018 (Million USD)

Continued….

At Any Query @ https://www.wiseguyreports.com/enquiry/3816922-global-artificial-knee-joint-market-data-survey-report-2013-2025

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US); Ph: +44 208 133 9349 (UK)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
+1 646-845-9349
email us here


Source: EIN Presswire

Global RTD Sensor Market Report 2020-2025 by Technology, Future Trends, Opportunities, Top Key Players and more…

A new market study, titled “Global RTD Sensor Market Research Report 2020”, has been featured on WiseGuyReports.

PUNE, MAHARASTRA, INDIA, February 27, 2020 /EINPresswire.com/ — RTD Sensor Market

This report focuses on RTD Sensor volume and value at global level, regional level and company level. From a global perspective, this report represents overall RTD Sensor market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.

At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Diodes Incorporated
Honeywell Sensing and Productivity Solutions
TE Connectivity Measurement Specialties
US Sensor
Vishay Beyschlag
OMEGA Engineering
Applied Measurement & Control
Onset Computer Corp
Jumo
Kimo Instruments
SensorTemp
Thermo-Kinetics Company Limited

Request Free Sample Report at https://www.wiseguyreports.com/sample-request/5010482-global-rtd-sensor-market-research-report-2020

Segment by Regions
North America
Europe
China
Japan
South Korea

Segment by Type
Industrial Platinum Resistance Thermometers
Standard Platinum Resistance Thermometers
Secondary Standard Platinum Resistance Thermometers

Segment by Application
Consumer Electronics
Power Generation
Automotive
Petrochemical
Healthcare
Industrial
Others

Table of Content:
1 Report Overview
2 Global Growth Trends
3 Market Share by Key Players
4 Breakdown Data by Type and Application
5 United States
6 Europe
7 China
8 Japan
9 Southeast Asia
10 India
11 Central & South America
12 International Players Profiles
13 Market Forecast 2020-2025
14 Analyst's Viewpoints/Conclusions
15 Appendix

View Detailed Report at https://www.wiseguyreports.com/reports/5010482-global-rtd-sensor-market-research-report-2020

About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
+1 646-845-9349
email us here


Source: EIN Presswire

CANNSUN MEDHEL GROUP PLC ANNOUNCES LETTER OF INTENT WITH MALAYSIAN BASED COMPANY FOR PHARMACEUTICAL PRODUCT DISTRIBUTION

This is the first step of Cannsun Medhel Group to enter Asia. We believe the addressable ASEAN market of 660 Million plus potential patients is where we want to be positioned for expansion.”

— Greg Bealer

ATHENS, GREECE, February 26, 2020 /EINPresswire.com/ — Cannsun Medhel Group PLC ("Cannsun" or the "Company"), is pleased to announce it has entered into a binding letter of intent (“LOI”) dated February 25th, 2020 with Borealis Healthcare Sdn Bhd (“Borealis”) pursuant to which the parties will form a joint venture company for the distribution of medical devices, pharmaceuticals, health and wellness products of Cannsun Medhel within Malaysia, Singapore and other agreed Asian markets.

Transaction

a. Initial Structure of Transaction: Cannsun has acquired 25% interest in Borealis Healthcare Sdn Bhd (“JVCo”). In consideration of the support and obligations to be provided by the Cannsun Group to JVCo as described herein. Borealis will have rights to use the name Cannsun Medhel.

b. Business: The business of the COMPANY will be the sale of fully EU certified and EU GMP compliant non-cannabis and cannabis based medical devices, pharmaceuticals, healthcare and wellness products (the “Products”) in the Territory. The Parties may mutually agree to expand the “Business” to include (i) partial packaging and/or manufacturing of a portion of the Products and (ii) the growing, manufacturing and distribution of medical cannabis and related products in the Territory;

c. Territory: (i) Malaysia; (ii) Singapore and (iii) such other additional countries/territories to be mutually agreed by the Parties. Where necessary, the Business in each jurisdiction (country/territory) will be carried out by separate joint venture companies incorporated based on terms identical to the JVCo;

d. Exclusive JVCo Rights: JVCo shall have the sole and exclusive right to carry out the Business in the Territory including importing, distributing, sales and to act as the authorized representative for all present and future products of the Cannsun Group in the Territory.

Upon execution of the Definitive Agreements the expected closing of the transaction is mid April 2020.

“This is the first step of Cannsun Medhel Group to enter Asia. We believe the addressable ASEAN market of 660 Million plus potential patients is where we want to be positioned for expansion. The ASEAN market is the fastest growing economy and our partner is well established in the market. We see this being a great opportunity for both companies. The Medhel brand established 1918 in Greece has a history of quality Medicines and Botanicals, and with Borealis we can expand this legacy to the ASEAN market. We see a 2nd phase of manufacturing products in Malaysia for the ASEAN market in 2021.” commented Greg Bealer, Director of Finance.

About Borealis
First established in 2019, Borealis Healthcare Sdn Bhd is a registered Malaysian company based and located in Kuala Lumpur, Malaysia. Its co-founders and management team, comprising Canadian and Malaysian partners, have worked together for more than 15 years delivering significant projects and establishing key networks globally and within the South East Asia region.

This joint venture with Cannsun-Medhel moves Borealis Healthcare forward in achieving its objectives of assisting professional healthcare providers continue to improve the healthcare they can provide, by bringing established, new and emerging healthcare products and services to Malaysia, Singapore and the other ASEAN nations. Cannsun-Medhel, building on its 103 year foundation of extensive pharmaceutical experience, its current EU GMP pharmaceutical manufacturing infrastructure, and EU certified products, will bring new options for healthcare providers, and investment to the region. This has the potential to improve healthcare and the quality of life for millions of people in the ASEAN region.

About Medhel
First established in 1918 and now with new management and ownership, Cannsun is re-emerging as a science-led, global, healthcare company focused on leveraging its existing infrastructure and reputation in the manufacture and distribution of established healthcare products and pharmaceuticals, as well as building a vertically integrated cannabis and cannabinoid division. The Company currently distributes products to thousands of healthcare professionals and pharmacies in 21 countries. Our current projected growth will enable us to deepen and extend our reach, so that we can help people everywhere live better, healthier lives.

www.cannsunmedhel.com

Contact:

David Parry
Chief Executive Officer
Phone: +30 693 603 5933
Email: david@cannsun.com

Ross Burnstad
Co-Founder | Managing Director
Phone: +60 12 217 3364
Email: ross.burnstad@borealis-group.com

Greg Bealer
Director of Finance
Phone: +1 780 970 3789
Email: g.bealer@cannsun.com

David Parry
Cannsun Medhel Group PLC
+1 604-889-2188
email us here


Source: EIN Presswire

CANNSUN MEDHEL GROUP PLC ANNOUNCES LETTER OF INTENT WITH MALYASIAN BASED COMPANY FOR PHARMACEUTICAL PRODUCT DISTRIBUTION

This is the first step of Cannsun Medhel Group to enter Asia. We believe the addressable ASEAN market of 660 Million plus potential patients is where we want to be positioned for expansion.”

— Greg Bealer

ATHENS, GREECE, February 26, 2020 /EINPresswire.com/ — Cannsun Medhel Group PLC ("Cannsun" or the "Company"), is pleased to announce it has entered into a binding letter of intent (“LOI”) dated February 25th, 2020 with Borealis Healthcare Sdn Bhd (“Borealis”) pursuant to which the parties will form a joint venture company for the distribution of medical devices, pharmaceuticals, health and wellness products of Cannsun Medhel within Malaysia, Singapore and other agreed Asian markets.

Transaction

a. Initial Structure of Transaction: Cannsun has acquired 25% interest in Borealis Healthcare Sdn Bhd (“JVCo”). In consideration of the support and obligations to be provided by the Cannsun Group to JVCo as described herein. Borealis will have rights to use the name Cannsun Medhel.

b. Business: The business of the COMPANY will be the sale of fully EU certified and EU GMP compliant non-cannabis and cannabis based medical devices, pharmaceuticals, healthcare and wellness products (the “Products”) in the Territory. The Parties may mutually agree to expand the “Business” to include (i) partial packaging and/or manufacturing of a portion of the Products and (ii) the growing, manufacturing and distribution of medical cannabis and related products in the Territory;

c. Territory: (i) Malaysia; (ii) Singapore and (iii) such other additional countries/territories to be mutually agreed by the Parties. Where necessary, the Business in each jurisdiction (country/territory) will be carried out by separate joint venture companies incorporated based on terms identical to the JVCo;

d. Exclusive JVCo Rights: JVCo shall have the sole and exclusive right to carry out the Business in the Territory including importing, distributing, sales and to act as the authorized representative for all present and future products of the Cannsun Group in the Territory.

Upon execution of the Definitive Agreements the expected closing of the transaction is mid April 2020.

“This is the first step of Cannsun Medhel Group to enter Asia. We believe the addressable ASEAN market of 660 Million plus potential patients is where we want to be positioned for expansion. The ASEAN market is the fastest growing economy and our partner is well established in the market. We see this being a great opportunity for both companies. The Medhel brand established 1918 in Greece has a history of quality Medicines and Botanicals, and with Borealis we can expand this legacy to the ASEAN market. We see a 2nd phase of manufacturing products in Malaysia for the ASEAN market in 2021.” commented Greg Bealer, Director of Finance.

About Borealis
First established in 2019, Borealis Healthcare Sdn Bhd is a registered Malaysian company based and located in Kuala Lumpur, Malaysia. Its co-founders and management team, comprising Canadian and Malaysian partners, have worked together for more than 15 years delivering significant projects and establishing key networks globally and within the South East Asia region.

This joint venture with Cannsun-Medhel moves Borealis Healthcare forward in achieving its objectives of assisting professional healthcare providers continue to improve the healthcare they can provide, by bringing established, new and emerging healthcare products and services to Malaysia, Singapore and the other ASEAN nations. Cannsun-Medhel, building on its 103 year foundation of extensive pharmaceutical experience, its current EU GMP pharmaceutical manufacturing infrastructure, and EU certified products, will bring new options for healthcare providers, and investment to the region. This has the potential to improve healthcare and the quality of life for millions of people in the ASEAN region.

About Medhel
First established in 1918 and now with new management and ownership, Cannsun is re-emerging as a science-led, global, healthcare company focused on leveraging its existing infrastructure and reputation in the manufacture and distribution of established healthcare products and pharmaceuticals, as well as building a vertically integrated cannabis and cannabinoid division. The Company currently distributes products to thousands of healthcare professionals and pharmacies in 21 countries. Our current projected growth will enable us to deepen and extend our reach, so that we can help people everywhere live better, healthier lives.

www.cannsunmedhel.com

Contact:

David Parry
Chief Executive Officer
Phone: +30 693 603 5933
Email: david@cannsun.com

Ross Burnstad
Co-Founder | Managing Director
Phone: +60 12 217 3364
Email: ross.burnstad@borealis-group.com

Greg Bealer
Director of Finance
Phone: +1 780 970 3789
Email: g.bealer@cannsun.com

David Parry
Cannsun Medhel Group PLC
+1 604-889-2188
email us here


Source: EIN Presswire